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Background/aim: Metabolic syndrome (MetS) is an important clinical issue in patients with schizophrenia, but its associated factors are
still ambiguous. The aim of the present study was to test whether there are any associations between MetS and white blood cell (WBC)
levels, liver enzymes, or sociodemographic variables.
Materials and methods: The study included 91 patients with a diagnosis of schizophrenia. We used the National Cholesterol Education
Program’s Third Adult Treatment Protocol criteria to evaluate MetS in patients. Schizophrenia patients with MetS were compared
with those without MetS on the basis of demographic and clinical characteristics and total WBC counts. We conducted Spearman’s
correlation and binary logistic regression analyses to achieve the best prediction of MetS in schizophrenia.
Results: Compared with schizophrenia patients without MetS, those with MetS were older, less educated, and more likely to be smokers.
They were also more likely to have a longer duration of the illness, a longer untreated period, and higher alanine aminotransferase
(ALT) and WBC levels. MetS was correlated with age, duration of illness, income, ALT, gamma-glutamyl transpeptidase, WBC, and
hemoglobin values. Age and WBC levels were found to be the best predictors of MetS.
Conclusion: Hemograms and liver tests should be conducted to test for MetS in schizophrenia.
Key words: Schizophrenia, metabolic syndrome, white blood cells, alanine aminotransferase

1. Introduction
The prevalence of metabolic syndrome (MetS) is higher
in people with schizophrenia than it is in the general
population (1). The rate of MetS, according to the National
Cholesterol Education Program’s Third Adult Treatment
Protocol (NCEP ATP III) criteria, was 40.9% in patients
who participated in the Clinical Antipsychotic Trials of
Intervention Effectiveness study (2). While there have
been many studies measuring the prevalence rates of
MetS in schizophrenia, there is limited information on the
factors related to MetS in schizophrenic patients.
Among the factors that increase the risk of MetS
are the use of antipsychotics, hyperphagia, diet-related
weight gain, smoking, low levels of physical activity,
difficulties dealing with stress, blood circulation
abnormalities, changing physiology of fat cells, sex
hormone abnormalities, changes in pituitary adrenal
functioning, some genetic polymorphisms, and
inflammation (3,4). Studies investigating the relationship
between sociodemographic and clinical variables such as
* Correspondence: semraulusoytr@yahoo.com

education level, employment, economic status, marriage,
age of illness onset, duration of illness, and number of
hospitalizations have had conflicting results (4,5). Only
age is consistently positively correlated with the rate of
MetS in patients with schizophrenia (6).
Research on the biological correlates of MetS in
schizophrenia must be improved. Hematologic parameters
such as the total white blood cell (WBC) count are among
these biological correlates. Recently, Na et al. (7) have
argued that a higher WBC count shows a low-grade
chronic inflammatory process in these particular patients.
In the literature, there are only a limited number of studies
investigating the WBC count as a risk factor for MetS in
patients with schizophrenia (7–9). Similarly, there are
few studies that investigated whether liver functions can
predict MetS in schizophrenia patients (10).
In the present study, we looked at MetS related factors
(demographic and clinical factors, along with total WBC
count and liver and thyroid function tests) in patients with
schizophrenia who were already undergoing treatment.
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2. Materials and methods
2.1. Participants
All participants were referred from the inpatient and
outpatient psychiatry clinic at Yıldırım Beyazıt Training
and Research Hospital. A total of 109 patients, diagnosed
with schizophrenia according to the Diagnostic and
Statistical Manual of Mental Disorders, 4th edition (DSMIV), were enrolled in the present study. We excluded from
the study 18 patients who did not consent to laboratory
tests. All participants and their families received
information about the study and signed the consent form,
giving their informed consent. The study was approved by
the Institutional Ethical Committee.
Patients between the ages of 18 and 25 and diagnosed
with schizophrenia according to the DSM-IV were included
in the study. Patients diagnosed with any psychiatric
disorder other than schizophrenia, patients diagnosed
with any type of metabolic disease (e.g., hypertension,
diabetes mellitus, and hyperlipidemia), patients using oral
contraceptives, or patients who were pregnant or breast
feeding were excluded from the study.
2.2. Procedure
All participants underwent a Structured Clinical Interview
for DSM-IV Axis I Disorders to confirm the diagnosis and
exclude other psychiatric diagnoses (11,12). As part of the
metabolic parameter analysis, the patients’ biochemical
and hematological measurements were determined using
venous blood that was collected in the morning after a
12-h fasting period. The height, weight, blood pressure,
and waist circumference of the patients were measured at
the same time. The height and weight were measured with
an electronic measurement device while the patients were
fasting. Blood pressure was measured on the left arm after
patients had rested for 5 min and while seated. We measured
the waist circumference above the highest point of the iliac
bone and at low respiration while patients were standing.
Medical histories, including treatment history, were
taken from the patients and their relatives (and/or those
who had lived with the patient and had information about
their history with the disease). We also inspected hospital
records.
Evaluations were carried out according to the 2001
NCEP ATP III criteria (13). According to these criteria,
patients were evaluated with regards to obesity (defined as
a waist circumference > 102 cm for men, and >88 cm for
women), triglyceride levels (>150 mg/dL was considered
hypertriglyceridemia), high density lipoprotein levels (≤40
mg/dL for men, and ≤50 mg/dL for women), blood pressure
(≥130/85 mmHg), and fasting blood glucose levels (≥10
mg/dL) A positive score in 4 of the 5 factors was accepted
as a MetS diagnosis. The patients were then divided into 2
groups according to these results: schizophrenia patients
with MetS and schizophrenia patients without MetS.
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2.3. Statistics
We analyzed the data using SPSS 17 (Chicago, IL, USA).
We used the Student’s t-test, chi-square tests, ANOVA, and
Spearman’s correlation and stepwise regression analyses. P
< 0.05 was considered significant.
3. Results
3.1. Demographics
We analyzed 91 patients who met the study criteria and
whose condition had remained stable over the 6 months
preceding the study. The demographics of the patient
groups are provided in Table 1. We found that 32.5% of all
patients had MetS. Table 1 shows that patients with MetS
were older than schizophrenia patients without MetS,
and the mean education level was lower in schizophrenia
patients with MetS than in those without MetS.
Smoking rates and duration of smoking were significantly
higher in schizophrenia patients with MetS than in patients
without MetS (t = 3.912, P = 0. 048 and t = 3. 222, P = 0.
002, respectively).
3.2. Clinical data
We found that, in the schizophrenia patients, the total
treatment period was an average of 31.9 months, the final
regular medication period was 12.7 months, and the total
disease period was an average of 114.1 months. The total
duration of psychosis was found to be 160.3 months in
the patients with MetS, and 89.1 months in the patients
without MetS. The duration of illness and untreated
psychosis was found to be longer in patients with MetS.
The 3 types of treatments applied to patients with
schizophrenia are atypical (69.2%), typical (6.6%), and
combined antipsychotics (24.2%). The medicines that
were most commonly used in treatment were olanzapine
(36.3%, n = 33), risperidone (31.9%, n = 29), and clozapine
(8.8%, n = 8). A daily dose of 525.2 mg of chlorpromazine
was found to be the average equivalent dose of the last
medication.
We did not find a significant relationship between the
two groups in terms of the type of antipsychotic. Likewise,
there was no difference between the chlorpromazineequivalent doses of the last medicine and the duration of
the medications between the groups (P > 0.05).
3.3. Laboratory data
Although 19.2% of patients in the study reported a
medical disease, only 12.1% of these patients were taking
medicine to treat their diseases. When the laboratory
results were examined, we found that the following
values were higher than normal: hemoglobin in 30.8% of
patients, total cholesterol in 5.5%, fasting blood glucose in
8.8%, triglycerides in 19.8%, aspartate aminotransferase
(AST) in 4.4%, alanine aminotransferase (ALT) in 14.3%,
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Table 1. Comparison of demographic characteristics between the two groups.
Schizophrenia with MetS* Schizophrenia without MetS
Mean ± SD†

Mean ± SD

P

t / χ2

Age

43.0 ± 10.6

31.7 ± 8.6

< 0.001

–5.519

Education (year)

7.4 ± 3.6

9.01 ± 3.4

0.035

2.137

Latest drug-free period (month)

2.80 ± 5.4

6.56 ± 10.6

0.030

2.186

Duration of total treatment (month)

15.57 ± 20.8

11.22 ± 20.5

0.340

–0.960

Duration of illness (month)

160.3 ± 87.5

89.1 ± 76.3

<0.001†

–4.037

n (%)

n (%)
0.637

0.222

0.058

3.605

0.287

1.133

0.528

0.397

0.048

3.912

0.712

0.136

0.202

1.627

Sex

Regular work

Income
Alcohol use
Smoking
Comorbid medical disease
A family history of
medical illness

Male

19

(37.3)

32

(62.7)

Female

13

(32.5)

27

(67.5)

Regular job

17

(53.1)

43

(72.9)

Unemployed

6

(18.8)

12

(20.3)

Retirement

9

(28.1)

4

(6.8)

Low

2

(6.3)

8

(13.6)

Middle/High

30

(93.8)

51

(86.4)

No

30

(93.8)

53

(89.8)

Yes

2

(6.3)

6

(10.2)

No

6

(18.8)

23

(39)

Yes

26

(81.3)

36

(61)

No

25

(78.1)

48

(81.4)

Yes

7

(21.9)

11

(18.6)

Yes

11

(34.4)

13

(22)

No

21

(65.6)

46

(78)

*MetS: metabolic syndrome.
SD†: standard deviation.
Bolded values are significant.

gamma-glutamyl transpeptidase (GGT) in 8.8%, and
thyroid-stimulating hormone (TSH) in 6.6%. In terms of
medical comorbidities, there was no difference between
schizophrenia patients with MetS and those without MetS.
A comparison of laboratory parameters between the
groups is shown in Table 2, where parameters of MetS are
represented along with thyroid function tests. All liver
enzymes were higher in the MetS group, but the difference
was significant only for the ALT (P = 0.008, t = –2.337)
values. In addition, the leukocyte count was higher (P <
0.01, t = –3.049) in patients with MetS.
3.4. Correlation analysis and binary regression analysis
MetS was correlated with age (r = 0.510, P < 0.001),
duration of illness (r = 0.372, P < 0.001), duration of
smoking (r = 0.387, P = 0.002), income (r = 0.237, P =
0.024), ALT (r = 0.257, P < 0.016), GGT (r = 0.417, P <
0.001), WBC (r = 0.344, P = 0.001), and hemoglobin levels
(r = 0.279, P = 0.009).

Binary regression analysis (backward conditional) was
conducted to construct a model for the best prediction
of MetS. Only significantly correlated factors underwent
regression analysis. The model was found to be significant
(P = 0.012), and the fitting of the model was acceptable
(r = 0.501). It represents a 73.9% specificity rate, a 90.9%
sensitivity rate, and an 85.1% total rate for the prediction
of MetS. The model of the regression analysis excluded
the following variables: GGT, ALT, hemoglobin, duration
of illness, and income. Age (B = 0.062, standard error =
0.013, Beta = 0.447, t = 4.704, P < 0.001) and WBCs (B =
0.167, standard error = 0.060, Beta = 0.282, t = 2.784, P =
0.007) were found to be predictors of MetS.
4. Discussion
In the general population the prevalence of MetS varies
from country to country. For example, in the United
States the frequency of MetS is 25%–34% in the general
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Table 2. Comparison of laboratory parameters between the two groups.

Weight (kg)

Schizophrenia with MetS*

Schizophrenia without MetS

Mean ± SD

Mean ± SD

†

88.4 ± 12.9

66.8 ± 11.6

P

t

<0 .001

–8.106

Systolic blood pressure (mmHg)

121.2 ± 16.9

111.0 ± 12.2

0.004

–3.008

Diastolic blood pressure (mmHg)

78.5 ± 10.4

73.3 ± 8.2

0.019

–2.611

Waist circumference (cm)

107.5 ± 9.7

85.8 ± 11.5

<0.001

–8.987

Triglycerides (mg/dL)

281.6 ± 113

126.1 ± 64.0

<0.001

–8.204

High-density lipoprotein (mg/dL)

32.9 ± 6.5

47.2 ± 11.0

<0.001

6.365

Fasting blood glucose (mg/dL)

103.6 ± 17.5

90.58 ± 13

0.001

–3.642

BMI (kg/m2)

32.0 ± 8.5

24.0 ± 7.4

<0.001

–7.401

TSH

1.5 ± 1.2

1.5 ± 0.9

0.805

0.248

T3

3.3 ± 0.8

3.4 ± 1.2

0.763

–0.304

T4

1.4 ± 0.5

1.4 ± 0.2

0.883

0.147

AST

21.4 ± 9.2

20.8 ± 8.0

0.585

0.270

ALT

27.2 ± 17.6

18.9 ± 12.0

0.008

–2.337

GGT

44.5 ± 4.4

30.9 ± 6.3

0.858

–1.049

ALP

178.4 ± 90.3

155.1 ± 53.7

0.247

–1.117

LDH

246.5 ± 125.4

220.1 ± 73.9

0.290

–0.914

Hemoglobin (g/dL)

14.3 ± 02.0

14.0 ± 63.5

0.73

–0.338

Leukocyte (K/uL)

8.72 ± 2.6

7.14 ± 1.7

<0.001

–3.049

Platelet (K/uL)

275.7 ± 90.2

257.7 ± 55.8

0.25

–1.157

*MetS: metabolic syndrome.
SD†: standard deviation.
Bolded values are significant.

population above the age of 20, and it is 23%–24% in Europe
for the same age group (14,15). A recent systematic review
reported that 32.5% of individuals with schizophrenia also
have MetS (6). In the Turkish Adult Risk Factor Study
conducted in 2000, the frequency of MetS was 28% in men
and 45% in women (16). In other studies, the prevalence of
MetS was found to range from 17.9% to 41.4% (17–19). We
see that MetS prevalence is higher in Turkey than it is in
Europe or in the United States. In our study, the MetS rate
was found to be 35.2% among patients with schizophrenia.
This result is in accordance with with the elevated presence
of MetS in the general Turkish population. A similar
interpretation was presented in one of the largest studies
from Turkey, which reported comparable results (20).
Schizophrenia patients with MetS were older than
those without MetS. Similarly, schizophrenia patients
with MetS had longer illness duration than those without
MetS. This could be coincidental, making it difficult to
determine whether age or length of disease is the main
factor affecting MetS. Both of these factors were found to
correlate with MetS in the Spearman’s correlation analysis,
but duration of illness had a weaker correlation (r = 0.372)
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than age (r = 0.510). Regression analysis supported only
age as a predictive factor. This finding is comparable with
the results of a recent metaanalysis (6).
One of the most interesting findings of the present study
was the relationship between WBC count and MetS. WBC
count was significantly higher in schizophrenia patients
with MetS than in those without MetS. WBC count was
mildly correlated with MetS in the correlation analysis,
while in the regression analysis it was one of the predictors
of MetS. Three previous studies reported that a higher WBC
count was associated with MetS (7–9). One of these studies
determined that changes in WBC count were positively
correlated with changes in waist circumference during a
24-week antipsychotic treatment period (7). In addition,
total WBC count predicted the future development of
MetS in the general population (9). The WBCs are known
to be a mediator of inflammation. What is the specific
meaning of this observed relationship for subjects with
schizophrenia? Inflammatory processes are blamed for
the etiology of not only MetS, but also of schizophrenia.
The coincidence of these two conditions seems to be high.
Patients with schizophrenia may have a predisposition
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to develop MetS independent of antipsychotic use (21).
Inflammation could be causatively connected to both
MetS and schizophrenia. These inflammatory processes
may originate from genetic factors, environmental factors,
or a combination of both.
The other original finding of the present study is
the association between ALT and MetS in subjects with
schizophrenia. ALT is a marker sensitive to nonalcoholic
fatty liver disease, which is strongly connected to the
existence of MetS (22). Recently, Kim et al. (10) reported
that ALT levels were associated with the incidence of MetS
in a longitudinal study of patients with schizophrenia.
Ekstedt et al. (23) had similar results with nonalcoholic
fatty liver disease patients. Lee et al. (24) published a
study showing an association between the prevalence

of MetS and ALT. In this regard, ALT could provide a
way to identify schizophrenic patients who are at risk of
developing MetS and who need intensive attention.
The main limitations of the present study are the small
sample size and the absence of healthy control groups.
Every patient with schizophrenia is a potential MetS
patient, and thus the prevention of MetS is crucial.
Follow-up with schizophrenia patients must be structured
not only for psychiatric clinical parameters, but also for
medical clinical parameters. Some routine laboratory
examinations, like total WBC and ALT tests, may help
to determine in advance the manifestation of MetS.
These findings may also enhance the understanding of
the underlying mechanisms of MetS in schizophrenia
patients.
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